Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricardo Caballero

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Expert Opinion on Investigational Drugs|September 5, 2022
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipelineJuan Tamargo, María Tamargo, Ricardo Caballero
Expert Opinion on Drug Safety|June 26, 2012
Drug-induced atrial fibrillationJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Investigational Drugs|December 8, 2018
New drugs in preclinical and early stage clinical development in the treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Cardiovascular Therapy|August 4, 2011
Ranolazine: an antianginal drug with antiarrhythmic propertiesJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|May 16, 2021
Sex-related differences in the pharmacological treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|January 7, 2026
SGLT2 inhibitors: Do they have antiarrhythmic properties?Ricardo Caballero, Juan Tamargo, Eva Delpón
Discovery Medicine|November 27, 2014
New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|February 23, 2021
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular diseaseJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Drug Safety|April 14, 2006
The safety of digoxin as a pharmacological treatment of atrial fibrillationJuan Tamargo, Eva Delpón, Ricardo Caballero
Discovery Medicine|December 4, 2012
Drug-induced atrial fibrillation: does it matter?Juan Tamargo, Ricardo Caballero, Eva Delpón
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|September 5, 2022
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipelineJuan Tamargo, María Tamargo, Ricardo Caballero
Expert Opinion on Drug Safety|June 26, 2012
Drug-induced atrial fibrillationJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Investigational Drugs|December 8, 2018
New drugs in preclinical and early stage clinical development in the treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Cardiovascular Therapy|August 4, 2011
Ranolazine: an antianginal drug with antiarrhythmic propertiesJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|May 16, 2021
Sex-related differences in the pharmacological treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|January 7, 2026
SGLT2 inhibitors: Do they have antiarrhythmic properties?Ricardo Caballero, Juan Tamargo, Eva Delpón
Discovery Medicine|November 27, 2014
New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|February 23, 2021
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular diseaseJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Drug Safety|April 14, 2006
The safety of digoxin as a pharmacological treatment of atrial fibrillationJuan Tamargo, Eva Delpón, Ricardo Caballero
Discovery Medicine|December 4, 2012
Drug-induced atrial fibrillation: does it matter?Juan Tamargo, Ricardo Caballero, Eva Delpón
Pageof 9